Published in Thromb Haemost on March 01, 2005
Serpins in thrombosis, hemostasis and fibrinolysis. J Thromb Haemost (2007) 1.60
Protein Z-dependent protease inhibitor deficiency produces a more severe murine phenotype than protein Z deficiency. Blood (2008) 1.06
Protein Z-dependent protease inhibitor and protein Z in peripheral arterial disease patients. J Thromb Haemost (2009) 0.95
A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. Blood (2006) 0.94
Low protein Z levels in children with nephrotic syndrome. Pediatr Nephrol (2006) 0.86
A meta-analysis of potential risks of low levels of protein Z for diseases related to vascular thrombosis. Thromb Haemost (2010) 0.83
Contribution of protein Z and protein Z-dependent protease inhibitor in generalized Shwartzman reaction. Crit Care Med (2013) 0.80
Changes in plasma levels of natural anticoagulants in disseminated intravascular coagulation: high prognostic value of antithrombin and protein C in patients with underlying sepsis or severe infection. Ann Lab Med (2014) 0.78
Computational study of the putative active form of protein Z (PZa): sequence design and structural modeling. Protein Sci (2008) 0.78
Pyelonephritis during pregnancy: a cause for an acquired deficiency of protein Z. J Matern Fetal Neonatal Med (2008) 0.78
Protein Z, protein Z-dependent protease inhibitor (serpinA10), and the acute-phase response. J Thromb Haemost (2013) 0.77
Protein Z Plasma Levels are Not Elevated in Patients with Non-Arteritic Anterior Ischemic Optic Neuropathy. Open Ophthalmol J (2009) 0.76
Association of the R67X and W303X non-sense polymorphisms in the protein Z-dependent protease inhibitor gene with idiopathic recurrent miscarriage. Mol Hum Reprod (2011) 0.75
Protein Z and protein Z-dependent protease inhibitor and renal tubules. Thromb Haemost (2009) 0.75
Protein Z and natural anticoagulants in children on peritoneal dialysis and hemodialysis. Pediatr Nephrol (2006) 0.75
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA (2005) 6.16
Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet (2011) 4.27
A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med (2013) 4.27
Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. JAMA (2007) 3.50
Estrogen plus progestin and risk of venous thrombosis. JAMA (2004) 3.46
Risk assessment for recurrent venous thrombosis. Lancet (2010) 3.31
Evaluation of short-term consequences of hypoglycemia in an intensive care unit. Crit Care Med (2006) 3.13
Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA (2005) 3.04
Prevention of venous thromboembolism after major orthopaedic surgery: is fondaparinux an advance? Lancet (2003) 2.98
Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA (2009) 2.85
Predisposing factors for hypoglycemia in the intensive care unit. Crit Care Med (2006) 2.75
Gene variants associated with deep vein thrombosis. JAMA (2008) 2.74
Osteoarthritis of the knee: association between clinical features and MR imaging findings. Radiology (2006) 2.62
Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ (2013) 2.45
Hypoglycemia is associated with intensive care unit mortality. Crit Care Med (2010) 2.41
Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol (2009) 2.37
Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev (2014) 2.28
Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med (2009) 2.26
Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients. Arch Intern Med (2009) 2.16
Risks of oral anticoagulant therapy with increasing age. Arch Intern Med (2005) 2.06
Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism. Arch Intern Med (2004) 2.00
Is an EMA review on hormonal contraception and thrombosis needed? BMJ (2013) 1.94
Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol (2008) 1.93
Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost (2003) 1.80
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood (2006) 1.78
High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood (2011) 1.78
Incidence and risk factors of early venous thrombosis associated with permanent pacemaker leads. J Cardiovasc Electrophysiol (2004) 1.72
Multiple SNP testing improves risk prediction of first venous thrombosis. Blood (2012) 1.70
Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA (2004) 1.70
Communication of biobanks' research results: what do (potential) participants want? Am J Med Genet A (2010) 1.69
Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol (2004) 1.69
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood (2012) 1.63
Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol (2007) 1.61
Smoking and the risk of mortality and vascular and respiratory events in patients undergoing major surgery. JAMA Surg (2013) 1.57
Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology (2004) 1.57
Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy. Br J Haematol (2010) 1.55
Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood (2006) 1.52
The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica (2005) 1.51
The effect of flight-related behaviour on the risk of venous thrombosis after air travel. Br J Haematol (2008) 1.50
Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med (2006) 1.50
Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies. J Clin Oncol (2008) 1.49
The risk of venous thrombosis in individuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors. Blood (2013) 1.47
Mutations in clotting factors and inflammatory bowel disease. Am J Gastroenterol (2006) 1.47
Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood (2005) 1.46
Subtherapeutic oral anticoagulant therapy: frequency and risk factors. Thromb Haemost (2009) 1.46
Bleeding in carriers of hemophilia. Blood (2006) 1.41
Factor V Leiden, prothrombin G20210A, and risk of sudden coronary death in apparently healthy persons. Am J Cardiol (2002) 1.41
[Bleeding time determination is out of date. A non-reliable method which should not be used in routine care]. Lakartidningen (2008) 1.40
Prothrombotic gene variation in patients with large and small vessel disease. Neuroepidemiology (2008) 1.40
Anti-prothrombin antibodies are associated with thrombosis in children. Thromb Res (2009) 1.40
Fluid loss does not explain coagulation activation during air travel. Thromb Haemost (2008) 1.38
Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation (2003) 1.32
Travel-related venous thrombosis: results from a large population-based case control study (MEGA study). PLoS Med (2006) 1.27
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics (2009) 1.25
Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood (2005) 1.25
Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA (2002) 1.23
Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol (2002) 1.22
Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke (2002) 1.21
A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med (2005) 1.20
ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood (2006) 1.18
Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood (2006) 1.18
The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition. Blood (2010) 1.18
Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood (2003) 1.17
Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis. Blood (2010) 1.17
Risk of failure of transvenous implantable cardioverter-defibrillator leads. Circ Arrhythm Electrophysiol (2009) 1.17
Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood (2010) 1.16
Risk factors for venous thrombosis - current understanding from an epidemiological point of view. Br J Haematol (2010) 1.16
Lethal perinatal thrombosis in mice resulting from the interaction of tissue factor pathway inhibitor deficiency and factor V Leiden. Circulation (2002) 1.15
Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica (2009) 1.15
Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol (2003) 1.14
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest (2002) 1.13
Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol (2005) 1.12
Inhibition of antithrombin by Plasmodium falciparum histidine-rich protein II. Blood (2011) 1.12
Quantification of bias in direct effects estimates due to different types of measurement error in the mediator. Epidemiology (2012) 1.11
Kinetic characterization of the protein Z-dependent protease inhibitor reaction with blood coagulation factor Xa. J Biol Chem (2008) 1.11
TFPIβ is the GPI-anchored TFPI isoform on human endothelial cells and placental microsomes. Blood (2011) 1.10
Formation of factors IXa and Xa by the extrinsic pathway: differential regulation by tissue factor pathway inhibitor and antithrombin III. J Biol Chem (2004) 1.10
Competing risk of atherosclerotic risk factors for arterial and venous thrombosis in a general population: the Tromso study. Arterioscler Thromb Vasc Biol (2011) 1.10
Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood (2004) 1.10
Does thrombophilia testing help in the clinical management of patients? Br J Haematol (2008) 1.07
Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J (2011) 1.07
Prevalence of colonisation with group B Streptococci in pregnant women of a multi-ethnic population in The Netherlands. Eur J Obstet Gynecol Reprod Biol (2005) 1.07
No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study. Arch Intern Med (2007) 1.06
Protein Z-dependent protease inhibitor deficiency produces a more severe murine phenotype than protein Z deficiency. Blood (2008) 1.06
Heart rate variability and first cardiovascular event in populations without known cardiovascular disease: meta-analysis and dose-response meta-regression. Europace (2013) 1.05
The relationship between exercise and risk of venous thrombosis in elderly people. J Am Geriatr Soc (2008) 1.05
The value of family history as a risk indicator for venous thrombosis. Arch Intern Med (2009) 1.04
Minor injuries as a risk factor for venous thrombosis. Arch Intern Med (2008) 1.04
SNPs in microRNA binding sites in 3'-UTRs of RAAS genes influence arterial blood pressure and risk of myocardial infarction. Am J Hypertens (2011) 1.03
Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood (2004) 1.03
Long-term survival in a large cohort of patients with venous thrombosis: incidence and predictors. PLoS Med (2012) 1.03
Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood (2013) 1.02
Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood (2008) 1.01
Inflammatory cytokines as risk factors for a first venous thrombosis: a prospective population-based study. PLoS Med (2006) 1.01